From: Adjuvant FOLFOX treatment for stage III colon cancer: how many cycles are enough?
Univariate COX regression | Multivariats logistic regression | |||||
---|---|---|---|---|---|---|
Hazard ratio | 95 % Cl | p value | Hazard ratio | 95 % Cl | p value | |
Sex (man vs woman) | 1.13 | 0.62–2.04 | 0.7 | |||
Age (≥70 years vs <70 years) | 1.22 | 0.65–2.23 | 0.53 | |||
T stage (4 vs 1–3) | 1.77 | 0.79–3.97 | 0.17 | 1.21 | 0.51–2.89 | 0.67 |
N stage (2 vs 1) | 1.31 | 0.73–2.37 | 0.37 | |||
Histo-pathological grade (poor differentiated vs. well, moderated differentiated) | 1.51 | 0.78 –5.23 | 0.35 | |||
Site (right vs left) | 1.1 | 0.61–1.98 | 0.76 | |||
Pre-operative CEA (≥ 5 vs. < 5) | 0.9 | 0.46–1.75 | 0.76 | |||
Performance status (1 and 2 vs.0) | 2.08 | 0.93–4.66 | 0.08 | 1.91 | 0.83–4.40 | 0.13 |
FOLFOX cycles (≥8 vs <8) | 0.54 | 0.30–0.99 | 0.043 | 0.52 | 0.28–0.97 | 0.038 |
Lymph nodes (≥12 vs. <12) | 3.1 | 0.75–12.89 | 0.12 | 2.9 | 0.68–12.31 | 0.15 |
Time to treatment (≥8 vs <8 weeks) | 1.71 | 0.61–4.79 | 0.31 | |||
Perforation or obstruction | 1.92 | 0.99–3.73 | 0.053 | 1.41 | 0.68–2.93 | 0.36 |